Express Scripts on deal for AbbVie's Viekira: more to come beyond hepatitis C
This article was originally published in Scrip
Executive Summary
Express Scripts set a precedent for new, high-priced drugs in the US when the pharmacy benefit manager (PBM) negotiated a deal with AbbVie that gives the pharma company's recently approved four-pill regimen Viekira Pak exclusive reimbursement for patients with genotype 1 hepatitis C.
You may also be interested in...
Express Scripts Adds Gilead’s Harvoni To 2017 Formularies
The pharmacy benefit manager says it has been able to negotiate a discount with Gilead enabling it to give both Harvoni and AbbVie’s Viekira Pak preferred formulary placement. Express Scripts also is expanding its indication-based oncology management initiative.
Industry Tightens Drug Pricing Message, But Loose Ends Remain
Drug makers are under increasing pressure regarding the cost of their medicines, but instead of pointing fingers at payers for patients' out-of-pocket costs, the industry has shifted to a more collaborative tone, although some tensions will take time to overcome.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.